Explorer The Edinburgh Consensus : Preparing for the advent of disease-modifying therapies for Alzheimer ' s disease
暂无分享,去创建一个
Nick C Fox | Brien | A. Waldman | M. Rossor | S. Lovestone | C. Holmes | Sube Banerjee | A. Burns | R. Perry | C. Ritchie | I. Leroi | Tom C. Russ | J. Pickett | J. Isaacs | Wai Lup Wong | B. Barber | Andrew Boaden | M. Norton | Jim Pearson | O. John
[1] B. de Strooper,et al. Alzheimer's disease: where next for anti-amyloid therapies? , 2017, Brain : a journal of neurology.
[2] Chengjie Xiong,et al. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model , 2017, Alzheimer's & Dementia.
[3] B. Dubois,et al. PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. , 2016, The journal of prevention of Alzheimer's disease.
[4] Azeem Majeed,et al. Rethinking primary care’s gatekeeper role , 2016, British Medical Journal.
[5] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[6] J. Cummings,et al. Alzheimer's drug-development pipeline: 2016 , 2016, Alzheimer's & dementia.
[7] K. Blennow,et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.
[8] José Luis Molinuevo,et al. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. , 2016, The lancet. Psychiatry.
[9] K. Yaffe,et al. Is late-onset Alzheimer's disease really a disease of midlife? , 2015, Alzheimer's & dementia.
[10] K. Blennow,et al. Amyloid biomarkers in Alzheimer's disease. , 2015, Trends in pharmacological sciences.
[11] Craig Ritchie,et al. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). , 2014, The Cochrane database of systematic reviews.
[12] M. Prince,et al. The Global Impact of Dementia 2013-2050 , 2013 .
[13] G. Mead,et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia , 2013, Alzheimer's & Dementia.
[14] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[15] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[16] B. Winblad,et al. Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.
[17] L. Whalley,et al. A life-course approach to the aetiology of late-onset dementias , 2006, The Lancet Neurology.